During a third phase of the pilot, set to begin in the third quarter of 2027, the EMA will open the program to IVD makers and notified bodies.

The assay delivers a risk score that can help clinicians to tailor treatment intensity to a patient's risk of disease progression.

NEW YORK — Cancer Check Labs said on Thursday that it has signed an agreement to offer its blood-based cancer screening test through Evexia Diagnostics' ordering platform. The test — called ...

Of the 30 companies in the index, 18 saw their share prices rise over the year, while 11 saw their stock prices decline and one remained flat. Readers this past year were most interested in a story ...